The COO of VIVEbiotech, José Manuel Franco, participated in a Roundtable of Ideas that took place at CIC bioGUNE. José María Mato, the General Director of the center, moderated the initiative, and Leire Bilbao, General Director of Innobasque, Ainara Basurko, General Director of BEAZ-BIZKAIA, Mikel Álvarez, Director of Business Development and Institutional Relations of Mondragon Corporation and Mr. Franco participated in it.

VIVEbiotech has participated in the 26th Congress of the European Society of Gene and Cell Therapy (ESGCT) that took place in Lausanne, Switzerland, on 16, 17, 18 and 19 October. It was a collaborative conference between the ESGCT, the ISSCR (International Society for Stem Cell Research) and the SFTCG (Société Française de Thérapie Cellulaire et Génique).

Dr. Juan Carlos Ramírez, Chief Scientific/Technology Officer of VIVEbiotech, participated in the informative symposium entitled "Present and Future Vision of Gene Therapy: 360º Approach" last Monday.

VIVEbiotech has signed three new contracts for the production of lentiviral vectors for three clinical trials for an amount of 1.4 million euros. Two of them are to supply lentiviruses to two European hospitals (one Spanish and one Swiss), and the third one to a Norwegian company.

Biospain is a biennial biotechnology event organized by Asebio (Spanish Association of Biocompanies) in which more than 3000 individual meetings are held and more than 800 companies participate. The last edition took place at the end of September in Seville.

VIVEbiotech S.L. has obtained the CIR certification (Crédit d'Impôt Recherche) which reinforces its position as an R & D provider for the French market.